Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, r...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2021-07-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12757 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729842261524480 |
|---|---|
| author | M. V. Shestakova M. B. Antsiferov A. S. Ametov G. R. Galstyan T. Y. Demidova A. M. Mkrtumyan N. A. Petunina |
| author_facet | M. V. Shestakova M. B. Antsiferov A. S. Ametov G. R. Galstyan T. Y. Demidova A. M. Mkrtumyan N. A. Petunina |
| author_sort | M. V. Shestakova |
| collection | DOAJ |
| description | Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, reducing a steady decrease in glycemia. To date, in clinical practice, various combinations of hypoglycemic drugs are used, the choice of which is determined by the characteristics of the course of diabetes in the patient, the presence of concomitant diseases and complications of diabetes, as well as the dominant clinical problem. This resolution provides an expert council opinion on the feasibility of using a combination of alogliptin and pioglitazone in patients with type 2 diabetes. |
| format | Article |
| id | doaj-art-e11b41f30f754ce09441600dfaac4c04 |
| institution | DOAJ |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2021-07-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-e11b41f30f754ce09441600dfaac4c042025-08-20T03:09:04ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782021-07-0124219319710.14341/DM1275710879Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatmentM. V. Shestakova0M. B. Antsiferov1A. S. Ametov2G. R. Galstyan3T. Y. Demidova4A. M. Mkrtumyan5N. A. Petunina6Endocrinology Research CentreEndocrinology Dispensary of the Moscow Department of HealthRussian Medical Academy of Continuous Professional EducationEndocrinology Research CentreThe Russian National Research Medical University named after N.I. PirogovA.I. Yevdokimov Moscow State University of Medicine and DentistryI.M. Sechenov First Moscow State Medical University (Sechenov University)Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, reducing a steady decrease in glycemia. To date, in clinical practice, various combinations of hypoglycemic drugs are used, the choice of which is determined by the characteristics of the course of diabetes in the patient, the presence of concomitant diseases and complications of diabetes, as well as the dominant clinical problem. This resolution provides an expert council opinion on the feasibility of using a combination of alogliptin and pioglitazone in patients with type 2 diabetes.https://www.dia-endojournals.ru/jour/article/view/12757diabetes mellitusalogliptinpioglitazonefixed combination |
| spellingShingle | M. V. Shestakova M. B. Antsiferov A. S. Ametov G. R. Galstyan T. Y. Demidova A. M. Mkrtumyan N. A. Petunina Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment Сахарный диабет diabetes mellitus alogliptin pioglitazone fixed combination |
| title | Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment |
| title_full | Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment |
| title_fullStr | Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment |
| title_full_unstemmed | Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment |
| title_short | Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment |
| title_sort | possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment |
| topic | diabetes mellitus alogliptin pioglitazone fixed combination |
| url | https://www.dia-endojournals.ru/jour/article/view/12757 |
| work_keys_str_mv | AT mvshestakova possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT mbantsiferov possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT asametov possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT grgalstyan possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT tydemidova possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT ammkrtumyan possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment AT napetunina possibilitiesofapplicationafixedcombinationofalogliptinandpioglitazonefortype2diabetesmellitustreatment |